Mayo Clinic’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Mayo Clinic’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22,577	Closed	-$88.5K	–	11
2023 Q3	$88.5K	Hold	22,577	–	–	0.17%	8
2023 Q2	$73.4K	Sell	22,577 -1,385	-6%	-$4.12K	0.08%	11
2023 Q1	$86.6K	Hold	23,962	–	–	0.07%	11
2022 Q4	$772K	Buy	+23,962	New	+$949K	0.41%	4
2021 Q2	$6.58M	Hold	23,962	–	–	7.28%	4
2021 Q1	$5.13M	Sell	23,962 -286	-1%	-$79K	5.9%	5
2020 Q4	$5.86M	Hold	24,248	–	–	7.05%	5
2020 Q3	$2.56M	Hold	24,248	–	–	3.44%	8
2020 Q2	$2.38M	Hold	24,248	–	–	2.27%	5
2020 Q1	$1.82M	Hold	24,248	–	–	4.61%	3
2019 Q4	$1.97M	Buy	+24,248	New	+$2.71M	2.23%	3

Other funds holding EVLO

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Mayo Clinic's EVLO Position: Q4 2023 in Review

Mayo Clinic sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 22,577 shares — an estimated $88.5K sold.

Mayo Clinic first reported a position in EVLO in Q4 2019 and held it in 11 quarters. The position peaked at $6.58M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.

Mayo Clinic reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Mayo Clinic sold 22,577 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $88.5K.
Mayo Clinic first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
Mayo Clinic's Evelo Biosciences, Inc. Common Stock position peaked at $6.58M in Q2 2021.
2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.

Based on Mayo Clinic's 13F filing for Q4 2023, filed 13 Feb 2024.